SRRK vs. RGNX, CCCC, CHRS, CPRX, DNLI, SWTX, ACLX, TWST, APGE, and NVAX
Should you be buying Scholar Rock stock or one of its competitors? The main competitors of Scholar Rock include REGENXBIO (RGNX), C4 Therapeutics (CCCC), Coherus BioSciences (CHRS), Catalyst Pharmaceuticals (CPRX), Denali Therapeutics (DNLI), SpringWorks Therapeutics (SWTX), Arcellx (ACLX), Twist Bioscience (TWST), Apogee Therapeutics (APGE), and Novavax (NVAX). These companies are all part of the "medical" sector.
Scholar Rock (NASDAQ:SRRK) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations, community ranking and profitability.
91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 26.2% of Scholar Rock shares are held by company insiders. Comparatively, 13.1% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Scholar Rock has a net margin of 0.00% compared to REGENXBIO's net margin of -299.96%. REGENXBIO's return on equity of -70.72% beat Scholar Rock's return on equity.
Scholar Rock has higher earnings, but lower revenue than REGENXBIO. Scholar Rock is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
In the previous week, Scholar Rock had 1 more articles in the media than REGENXBIO. MarketBeat recorded 5 mentions for Scholar Rock and 4 mentions for REGENXBIO. Scholar Rock's average media sentiment score of 0.49 beat REGENXBIO's score of 0.00 indicating that Scholar Rock is being referred to more favorably in the media.
Scholar Rock currently has a consensus target price of $25.17, indicating a potential upside of 164.63%. REGENXBIO has a consensus target price of $38.58, indicating a potential upside of 174.03%. Given REGENXBIO's higher probable upside, analysts clearly believe REGENXBIO is more favorable than Scholar Rock.
REGENXBIO received 275 more outperform votes than Scholar Rock when rated by MarketBeat users. Likewise, 65.79% of users gave REGENXBIO an outperform vote while only 63.56% of users gave Scholar Rock an outperform vote.
Scholar Rock has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.
Summary
Scholar Rock beats REGENXBIO on 10 of the 19 factors compared between the two stocks.
Get Scholar Rock News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scholar Rock Competitors List
Related Companies and Tools
